Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Lung Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
80 drugs · 288 active trials
21 drugs · 611 active trials
51 drugs · 1,372 active trials
Outside the funnel: Phase not stated 2 · Withdrawn 2. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 14 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Lenvatinib | Phase 3 | Phase 3 | 3 | 0 | 4 | 14 | 0 | — | — | 2009-02 |
| Veliparib | Phase 3 | Phase 3 | 3 | 0 | 2 | 14 | 0 | — | — | 2011-01 |
| Capecitabine | Phase 3 | Phase 3 | 3 | 1 | 1 | 13 | 0 | — | — | 2004-12 |
| Talazoparib | Phase 3 | Phase 3 | 3 | 0 | 1 | 10 | 0 | — | — | Jan 3, 2011 |
| Niraparib | Phase 3 | Phase 3 | 3 | 1 | 1 | 8 | 0 | — | — | Aug 29, 2017 |
| Vemurafenib | Phase 3 | Phase 3 | 3 | 2 | 2 | 5 | 0 | — | — | May 12, 2017 |
| Ceritinib | Phase 3 | Phase 3 | 2 | 0 | 2 | 18 | 0 | — | — | Jan 24, 2011 |
| Cediranib | Phase 3 | Phase 3 | 2 | 0 | 2 | 15 | 0 | — | — | Jan 21, 2005 |
| Palbociclib | Phase 3 | Phase 3 | 2 | 1 | 1 | 12 | 0 | — | — | 2011-02 |
| TAK-788 | Phase 3 | Phase 3 | 2 | 0 | 1 | 4 | 0 | — | — | Jun 16, 2016 |
| Adjuvant Chemotherapy | Phase 3 | Phase 3 | 2 | 0 | 1 | 3 | 0 | — | — | 1999-09 |
| Camrelizumab | Phase 3 | Phase 3 | 1 | 0 | 5 | 30 | 0 | — | — | Mar 13, 2017 |
| Doxorubicin | Phase 3 | Phase 3 | 1 | 1 | 5 | 15 | 0 | — | — | 1993-01 |
| Vorinostat | Phase 3 | Phase 3 | 1 | 0 | 1 | 15 | 0 | — | — | 2005-06 |
| Aspirin | Phase 3 | Phase 3 | 1 | 0 | 2 | 8 | 0 | — | — | 2010-08 |
| Tretinoin | Phase 3 | Phase 3 | 1 | 1 | 1 | 8 | 0 | — | — | 1998-09 |
| Mitomycin | Phase 3 | Phase 3 | 1 | 1 | 5 | 7 | 0 | — | — | 1995-10 |
| Axitinib | Phase 3 | Phase 3 | 1 | 0 | 1 | 6 | 0 | — | — | 2005-02 |
| Retifanlimab | Phase 3 | Phase 3 | 1 | 1 | 1 | 6 | 0 | — | — | Feb 27, 2015 |
| Denosumab | Phase 3 | Phase 3 | 1 | 1 | 1 | 4 | 0 | — | — | Nov 16, 2009 |
| Fexagratinib | Phase 3 | Phase 3 | 1 | 0 | 1 | 4 | 0 | — | — | Jan 15, 2014 |
| Nogapendekin Alfa Inbakicept | Phase 3 | Phase 3 | 1 | 1 | 1 | 2 | 0 | — | — | May 29, 2026 |
| Setidegrasib | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | Apr 28, 2026 |
| Celecoxib | Phase 3 | Phase 3 | 0 | 0 | 3 | 29 | 0 | — | — | 2000-12 |
| Vandetanib | Phase 3 | Phase 3 | 0 | 0 | 4 | 24 | 0 | — | — | 2002-10 |
| Sorafenib | Phase 3 | Phase 3 | 0 | 0 | 1 | 19 | 0 | — | — | 2004-04 |
| Pazopanib | Phase 3 | Phase 3 | 0 | 0 | 2 | 18 | 0 | — | — | 2006-11 |
| Ifosfamide | Phase 3 | Phase 3 | 0 | 0 | 6 | 10 | 0 | — | — | 1995-10 |
| Rovalpituzumab Tesirine | Phase 3 | Phase 3 | 0 | 0 | 3 | 10 | 0 | — | — | 2013-07 |
| Poziotinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 8 | 0 | — | — | 2013-03 |
| Onartuzumab | Phase 3 | Phase 3 | 0 | 0 | 3 | 7 | 0 | — | — | 2009-04 |
| Motesanib | Phase 3 | Phase 3 | 0 | 0 | 2 | 6 | 0 | — | — | 2004-12 |
| Naquotinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 6 | 0 | — | — | Jan 23, 2014 |
| Rociletinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 6 | 0 | — | — | Mar 27, 2012 |
| Bexarotene | Phase 3 | Phase 3 | 0 | 0 | 1 | 5 | 0 | — | — | 2001-08 |
| Fruquintinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 5 | 0 | — | — | May 29, 2014 |
| Ganetespib | Phase 3 | Phase 3 | 0 | 0 | 1 | 5 | 0 | — | — | 2009-11 |
| Ponatinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 5 | 0 | — | — | 2013-01 |
| Eribulin | Phase 3 | Phase 3 | 0 | 0 | 1 | 4 | 0 | — | — | 2006-11 |
| Picoplatin | Phase 3 | Phase 3 | 0 | 0 | 1 | 4 | 0 | — | — | 2005-06 |
| Vincristine | Phase 3 | Phase 3 | 0 | 0 | 3 | 4 | 0 | — | — | 1993-01 |
| Epirubicin | Phase 3 | Phase 3 | 0 | 0 | 2 | 3 | 0 | — | — | 1996-03 |
| Vindesine | Phase 3 | Phase 3 | 0 | 0 | 2 | 3 | 0 | — | — | 1995-02 |
| Lonafarnib | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | 2002-12 |
| Lucitanib | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | 2014-04 |
| Patritumab | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | 2010-09 |
| Rilotumumab | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | Dec 2, 2008 |
| Dinutuximab | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | Jun 1, 2017 |
| Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | Jun 1, 2019 |
| Megestrol | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | Sep 1, 2000 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.